They are still recruiting and when I first published I forgot to stress that Prozac is also part of the clinical trial.
It is Cymbalta (duloxetine) and Prozac (fluoxetine).
- Children of site personnel directly affiliated with this study and/or their immediate families.
- Children of Lilly employees or employees of the designated CRO assisting with the conduct of the study.
Extracts from the government page:
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
This study is currently recruiting participants.
Verified by Eli Lilly and Company, September 2009
First Received: February 23, 2009 Last Updated: September 14, 2009 History of Changes
Sponsored by: | Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00849693 |
The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
Condition | Intervention | Phase |
---|---|---|
Major Depressive Disorder | Drug: Placebo Drug: fluoxetine Drug: duloxetine | Phase III |
Estimated Enrollment: | 448 |
Study Start Date: | March 2009 |
Estimated Study Completion Date: | March 2012 |
Estimated Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 7 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Outpatient, diagnosed with MDD as defined by the DSM-IV-TR and supported by the MINI-KID.
- Diagnosis of moderate or greater severity of MDD as determined by CDRS-R with a total score greater than or equal to 40 at screen, and randomization and a CGI-Severity rating of greater than or equal to 4 at screen, and randomization.
- Female patients must test negative for pregnancy during screening.
- Judged to be reliable by the investigator to keep all appointments for clinical visits, tests, and procedures required by the protocol.
- Has a degree of understanding such that they can communicate intelligently with the investigator and study coordinator.
- Capable of swallowing study drug whole. It is anticipated the patients will need to swallow up to 6 capsules per day.
- Patients must have venous access sufficient to allow blood sampling and are compliant with blood draws as per the protocol.
Exclusion Criteria:
- Children of site personnel directly affiliated with this study and/or their immediate families.
- Children of Lilly employees or employees of the designated CRO assisting with the conduct of the study.
ClinicalTrials.gov processed this record on October 20, 2009
Contact Help Desk
Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
U.S. National Institutes of Health, U.S. Department of Health & Human Services,
USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act
No comments:
Post a Comment